Status:
TERMINATED
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemothera...
Detailed Description
PF-3512676 dosing was stopped 21 June 2007 when Pfizer decided to stop the administration of PF-3512676 in all trials which combined PF-3512676 with cytotoxic chemotherapy. The decision was made subse...
Eligibility Criteria
Inclusion
- Locally advanced or metastatic NSCLC
- Measurable disease
- ECOG PS 0 or 1
Exclusion
- Known CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00321308
Start Date
September 1 2006
End Date
January 1 2008
Last Update
September 28 2009
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Litchfield Park, Arizona, United States, 85340
2
Pfizer Investigational Site
Sun City, Arizona, United States, 85351
3
Pfizer Investigational Site
Bentonville, Arkansas, United States, 72712
4
Pfizer Investigational Site
Fayetteville, Arkansas, United States, 72703